Retatrutide (LY-3437943) is an investigational drug developed by Eli Lilly that acts as a triple hormone receptor agonist : GLP-1 (glucagon-like peptide-1) receptor agonist GIP (glucose-dependent insulinotropic polypeptide) receptor agonist Glucagon receptor agonist - read about why this is so important here This triagonist approach amplifies the metabolic impact seen with GLP-1 and GIP combinations like tirzepatide, while also leveraging glucagons thermogenic and energy-expending properties
Variants like GLP1R rs6923761 and FTO rs9939609 can suggest how your body may respond to GLP-1 agonism, informing whether you might benefit from optimized monotherapyoften enough to avoid the risks of dual-agent approaches
Compounded Medications vs
These findings show that semaglutide works well in a variety of patient populations, though results can vary from person to person
Efficacy for glycemic control : Clinical trials of semaglutide (SUSTAIN program) have demonstrated hemoglobin A1c reductions of 1.5-2.0% in patients with type 2 diabetes, with many patients achieving A1c levels below 7%
The list price of tirzepatide is $1,112.16 per month for Mounjaro and $1,086.37 per month for Zepbound pens, but there are ways to reduce those costs, such as manufacturer savings cards and paying with cash
